研究单位：[1]Nanfang Hospital of Southern Medical University[2]Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China[3]302 Military Hospital of China BeiJing, Beijing, China[4]Beijing Ditan Hospita Beijing, Beijing, China[5]Beijing Friendship Hospital Attached to the Capital Medical University Beijing, Beijing, China[6]BeiJing YouAn Hospital ,Capital Medical University BeiJing, Beijing, China[7]Department of infectious disease, First Hospital of Peking University Beijing, Beijing, China[8]People'S Hospital Under Beijnig University Beijing, Beijing, China[9]The Second Affiliated of ChongQing University of Medical Science ChongQing, Chongqing, China[10]Department of infectious disease, Nanfang Hospital Guangzhou, Guangdong, China[11]No. 8 People's Hospital In GuangZhou GuangZhou, Guangdong, China[12]The Third Hospital of Sun Yat-Sen University GuangZhou, Guangdong, China[13]Xiangya Hospital Central-South Univrsity ChangSha, Hunan, China[14]No.81 Hospital of PLA NanJing, Jiangsu, China[15]First Hospital .Jilin Unniversity ChangChun, Jilin, China[16]ShengJing Hospital of China Medical University ShenYang, Liaoning, China[17]JiNan Infectious Diseases Hospital JINan, Shandong, China[18]Changhai Hospital affiliated to Second Military Medical University ShangHai, Shanghai, China[19]Huashan Hospital，Fudan University ShangHai, Shanghai, China[20]No.85 Hospital of PLA ShangHai, Shanghai, China[21]Shanghai Ruijin Hospital ShangHai, Shanghai, China[22]Tangdu Hospital XiAn, Shanxi, China[23]West China Hospital.SiChuan University ChengDu, Sichuan, China[24]The First Affiliated Hospital of College of Medicine ，Zhejiang University HangZhou, Zhejiang, China[25]The Sixth People's Hospital of Hangzhou Hangzhou, Zhejiang, China
The purpose of this trial is to prove that the strategy of treatment adjustment at W24 according to virological response based on ROADMAP concept is better than standard of care strategy.
